Cargando…

Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report

Current therapeutic modalities for ovarian cancer such as chemotherapy, radiotherapy and surgery have been reported to yield only marginal success in improving survival rates of patients and have associated adverse effects. We report here a case of recurrent stage IV ovarian cancer, treated with cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Manjunath, Sadananda Rao, Ramanan, Ganapathi, Dedeepiya, Vidyasagar Devaprasad, Terunuma, Hiroshi, Deng, Xuewen, Baskar, Subramani, Senthilkumar, Rajappa, Thamaraikannan, Paramasivam, Srinivasan, Thangavelu, Preethy, Senthilkumar, Abraham, Samuel J.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364094/
https://www.ncbi.nlm.nih.gov/pubmed/22666198
http://dx.doi.org/10.1159/000337319
_version_ 1782234483322257408
author Manjunath, Sadananda Rao
Ramanan, Ganapathi
Dedeepiya, Vidyasagar Devaprasad
Terunuma, Hiroshi
Deng, Xuewen
Baskar, Subramani
Senthilkumar, Rajappa
Thamaraikannan, Paramasivam
Srinivasan, Thangavelu
Preethy, Senthilkumar
Abraham, Samuel J.K.
author_facet Manjunath, Sadananda Rao
Ramanan, Ganapathi
Dedeepiya, Vidyasagar Devaprasad
Terunuma, Hiroshi
Deng, Xuewen
Baskar, Subramani
Senthilkumar, Rajappa
Thamaraikannan, Paramasivam
Srinivasan, Thangavelu
Preethy, Senthilkumar
Abraham, Samuel J.K.
author_sort Manjunath, Sadananda Rao
collection PubMed
description Current therapeutic modalities for ovarian cancer such as chemotherapy, radiotherapy and surgery have been reported to yield only marginal success in improving survival rates of patients and have associated adverse effects. We report here a case of recurrent stage IV ovarian cancer, treated with cell-based autologous immune enhancement therapy (AIET) along with chemotherapy and followed up for 18 months. A 54-year-old female was diagnosed with a recurrence of ovarian carcinoma 1 year after initial surgical removal followed by chemotherapy for stage IIIC ovarian carcinoma. When diagnosed in 2010 with recurrence, she had liver and spleen metastases with a CA-125 level of 243 U/ml and a stage IV clinical status. Six infusions of AIET using autologous in vitro expanded and activated natural killer (NK) cells (CD3–CD56+) and activated T lymphocytes (CD3+CD56+) were administered in combination with 6 cycles of chemotherapy with carboplatin and doxorubicin. Following this treatment, CA-125 decreased to 4.7 U/ml along with regression of the metastatic lesions and an improved quality of life. No adverse reactions were reported after the AIET transfusions. Eighteen months of follow-up revealed a static nonprogressive disease. Combining AIET with chemotherapy and other conventional treatments has been found to be effective in our experience, as reported earlier, even in patients with advanced ovarian cancer, and we recommend this strategy be considered in treating similar cases.
format Online
Article
Text
id pubmed-3364094
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-33640942012-06-04 Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report Manjunath, Sadananda Rao Ramanan, Ganapathi Dedeepiya, Vidyasagar Devaprasad Terunuma, Hiroshi Deng, Xuewen Baskar, Subramani Senthilkumar, Rajappa Thamaraikannan, Paramasivam Srinivasan, Thangavelu Preethy, Senthilkumar Abraham, Samuel J.K. Case Rep Oncol Published online: March, 2012 Current therapeutic modalities for ovarian cancer such as chemotherapy, radiotherapy and surgery have been reported to yield only marginal success in improving survival rates of patients and have associated adverse effects. We report here a case of recurrent stage IV ovarian cancer, treated with cell-based autologous immune enhancement therapy (AIET) along with chemotherapy and followed up for 18 months. A 54-year-old female was diagnosed with a recurrence of ovarian carcinoma 1 year after initial surgical removal followed by chemotherapy for stage IIIC ovarian carcinoma. When diagnosed in 2010 with recurrence, she had liver and spleen metastases with a CA-125 level of 243 U/ml and a stage IV clinical status. Six infusions of AIET using autologous in vitro expanded and activated natural killer (NK) cells (CD3–CD56+) and activated T lymphocytes (CD3+CD56+) were administered in combination with 6 cycles of chemotherapy with carboplatin and doxorubicin. Following this treatment, CA-125 decreased to 4.7 U/ml along with regression of the metastatic lesions and an improved quality of life. No adverse reactions were reported after the AIET transfusions. Eighteen months of follow-up revealed a static nonprogressive disease. Combining AIET with chemotherapy and other conventional treatments has been found to be effective in our experience, as reported earlier, even in patients with advanced ovarian cancer, and we recommend this strategy be considered in treating similar cases. S. Karger AG 2012-03-16 /pmc/articles/PMC3364094/ /pubmed/22666198 http://dx.doi.org/10.1159/000337319 Text en Copyright © 2012 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No-Derivative-Works License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions.
spellingShingle Published online: March, 2012
Manjunath, Sadananda Rao
Ramanan, Ganapathi
Dedeepiya, Vidyasagar Devaprasad
Terunuma, Hiroshi
Deng, Xuewen
Baskar, Subramani
Senthilkumar, Rajappa
Thamaraikannan, Paramasivam
Srinivasan, Thangavelu
Preethy, Senthilkumar
Abraham, Samuel J.K.
Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report
title Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report
title_full Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report
title_fullStr Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report
title_full_unstemmed Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report
title_short Autologous Immune Enhancement Therapy in Recurrent Ovarian Cancer with Metastases: A Case Report
title_sort autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report
topic Published online: March, 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364094/
https://www.ncbi.nlm.nih.gov/pubmed/22666198
http://dx.doi.org/10.1159/000337319
work_keys_str_mv AT manjunathsadanandarao autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT ramananganapathi autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT dedeepiyavidyasagardevaprasad autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT terunumahiroshi autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT dengxuewen autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT baskarsubramani autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT senthilkumarrajappa autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT thamaraikannanparamasivam autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT srinivasanthangavelu autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT preethysenthilkumar autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport
AT abrahamsamueljk autologousimmuneenhancementtherapyinrecurrentovariancancerwithmetastasesacasereport